Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria

Microcrystalline Tyrosine (MCT®) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria. To this end, we formulated the circumsporozoite protein...

ver descrição completa

Detalhes bibliográficos
Principais autores: Gustavo Cabral-Miranda, Matthew D. Heath, Ariane C. Gomes, Mona O. Mohsen, Eduardo Montoya-Diaz, Ahmed M. Salman, Erwan Atcheson, Murray A. Skinner, Matthias F. Kramer, Arturo Reyes-Sandoval, Martin F. Bachmann
Formato: Artigo
Idioma:English
Publicado em: MDPI AG 2017-09-01
coleção:Vaccines
Assuntos:
Acesso em linha:https://www.mdpi.com/2076-393X/5/4/32